4NCCN.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology,Breast Cancer[EB/OL].(2012-09-14)[2012-12-01].http://www.nccn.org/professionals/physician_ gls/f _ guidelines.asp #breast.
5Hershman D L,Shao T,Kushi L H,et al.Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer[J].Breast Cancer Res Treat,2011,126(2):529-537.
6Liu H,Colin C E,Miller L G,et al.A comparison study of multiple measures of adherence to HIV protease inhi-bitors[J].Ann Intern Med,2001,134(10):968-977.
7Darkow T,Henk H J,Thomas S K,et al.Treatment interruptions and non-adherence with imatinib and associated healthcare costs:a retrospective analysis among managed care patients with chronic myelogenous leukaemia[J].Pharmacoeconomics,2007,25 (6):481-496.
8Noens L,van Lierde M A,De Bock R,et al.Prevalence,determinants,and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia:the ADAGIO study[J].Blood,2009,113(22):5401-5411.
9Ziller V,Kalder M,Albert U S,et al.Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer[J].Ann Oncol,2009,20 (3):431-436.
10Fink A K,Gurwitz J,Rakowski W,et al.Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer[J].J Clin Oncol,2004,22(16):3309-3315.
